Liquidia stock slides after Needham swaps LQDA off its 2026 Conviction List
Liquidia shares dropped 6.2% to $30.17 Tuesday after Needham removed the stock from its 2026 “Conviction List.” The decline came as biotech ETFs rose. Investors are focused on Yutrepia’s prescription growth and the next quarterly update in March. Liquidia’s stock remains volatile amid competition and legal risks.